-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price Target

Benzinga·06/23/2026 12:20:32
Listen to the news
Wedbush analyst David Nierengarten reiterates TScan Therapeutics (NASDAQ:TCRX) with a Outperform and maintains $5 price target.